deltatrials
Completed PHASE2 INTERVENTIONAL NCT00362050

RBx11160 Phase II Dose Ranging Study RBx/MMV05-06

A Phase II, Double-Blind, Parallel-Group, Randomized, Dose-Ranging Study Assessing the Antimalarial Activity and Safety of RBx 11160 Administered for 7 Days in Patients With Acute Uncomplicated Plasmodium Falciparum Malaria

Sponsor: Medicines for Malaria Venture

Conditions Plasmodium Falciparum Malaria
Interventions Treatment with 3 dose groups of RBx11160 over 7 days
Updated 5 times since 2017 Last updated: Aug 28, 2007 Started: Jun 30, 2006 Completion: Jan 31, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Plasmodium Falciparum Malaria, this trial is completed. The trial is conducted by Medicines for Malaria Venture and has accumulated 5 data snapshots since 2006. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Medicines for Malaria Venture
  • Ranbaxy Laboratories Limited
  • Swiss Tropical & Public Health Institute
Data source: Medicines for Malaria Venture

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations